FRANCE – bioMérieux, a key player in the global in vitro diagnostics arena, has partnered with BrightInsight to develop and market a digital clinical decision support tool for multiple disease areas covered by its IVD tests.
This solution, which will be based on BrightInsight’s regulated disease management will improve clinical workflows, contextualize disease awareness, and ultimately enable a more holistic patient view to support clinicians in making actionable, informed decisions.
The aim is to improve clinical workflows and deliver actionable data to cross-functional care teams, the companies said.
“Our engagement with BrightInsight will enable us to bring our digital health solutions to market faster with the goal of improving patient outcomes,” Brian Armstrong, senior vice president of clinical operations at BioMérieux North America, said in a statement.
bioMérieux’s Clinical Digital Solution will launch first in the US, with planned global expansion, the firms said.
BrightInsight on its part is behind AstraZeneca’s Amaze chronic disease management platform, which the pharma giant sold to Huma in March. BrightInsight’s more recent partners include Sanofi and UCB.
BrightInsight last year raised over US$100 million in venture funds and counts leading healthtech VCs, including General Catalyst, among its backers.
Just recently, BrightInsight launched the BrightInsight Ecosystem, a network of the world’s leading healthcare and technology companies collaborating to solve the biggest healthcare challenges to drive digital innovation, adoption, and engagement.
BrightInsight is partnering with Lyniate to improve information exchange for regulated digital health solutions built on the BrightInsight Platform.
Lyniate solutions are at work in 7,000 healthcare information-sharing deployments, connecting more than 1 million data endpoints across more than 1,700 healthcare organizations across 60 countries.
Antimicrobial resistance joint venture
Earlier in July, bioMérieux, Boehringer Ingelheim, and Evotec SE created a joint venture targeting antimicrobial resistance (AMR) named Aurobac Therapeutics SAS.
The JV was created with the aim of taking a precision medicine approach to tackling antimicrobial resistance (AMR), one of the most pressing worldwide public health challenges through the development of next-generation antimicrobial agents along with actionable diagnostics.
Antibiotic treatment regimens currently lean heavily on empirical approaches using broad-spectrum and unfocused medicines.
The goal is to turn this into a precision approach, using new highly effective, and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.
Aurobac Therapeutics will combine the best capabilities of the three founding companies.